Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 40

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 40
---
 shares are listed on the
Nasdaq Capital Market under the symbol “EDSA.” On July 23, 2025, the last reported sale price of our common shares as reported
on the Nasdaq Capital Market was $2.38 per share. We have not yet determined whether the other securities that may be offered by this
prospectus will be listed on any exchange, inter-dealer quotation system or over-the-counter market. If we decide to seek the listing
of any such securities upon issuance, the prospectus supplement relating to those securities will disclose the exchange, quotation system
or market on which the securities will be listed.

As of July 25, 2025, the aggregate
market value of our outstanding common shares held by non-affiliates, or the public float, was $13,944,175.92, based on 7,029,750 common
shares outstanding, of which 5,738,344 shares were held by non-affiliates, and a price of $2.43 per share, which was the last reported
sale price of our common shares on the Nasdaq Capital Market on July 22, 2025. Pursuant to General Instruction I.B.6 of Form S-3, in no
event will we sell shares pursuant to this prospectus with a value of more than one-third of the aggregate market value of our common
shares held by non-affiliates in any 12-month period, so long as the aggregate market value of our common shares held by non-affiliates
is less than $75,000,000. During the 12 calendar months prior to, and including, the date of this prospectus, we have sold securities
with an aggregate market value of $837,134 pursuant to General Instruction I.B.6. of Form S-3.

Investing in our securities involves certain risks. See “Risk Factors” in our most recent Annual Report on Form 10-K as such risk factors may be updated in our subsequent reports filed with the Securities and Exchange Commission, which are incorporated by reference herein, and as may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is September 9, 202